Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
15 hedge funds and large institutions have $3.9M invested in Interpace Biosciences, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 5 closing their positions.
10% more capital invested
Capital invested by funds: $3.55M → $3.9M (+$345K)
12% less funds holding
Funds holding: 17 → 15 (-2)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$608K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$79.4K |
| 3 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$51.9K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$4.5K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$188 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$43K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$39.7K |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$27K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
-$13K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$11K |
IDXG Hedge Fund Activity: Q1 2020 in Review
15 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q1 2020, worth a combined $3.9M — up 9.7% from $3.55M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IDXG and 4 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 3 added.
The largest buyer was Stonepine Capital Management, adding an estimated $608K. The largest seller was Northern Trust, exiting entirely with an estimated $43K sold.
- 15 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q1 2020, down from 17 in Q4 2019.
- Funds reported $3.9M of Interpace Biosciences, Inc. Common Stock stock for Q1 2020, up 9.7% quarter-over-quarter.
- 4 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q1 2020 and 5 closed out, a net change of -1 holder.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q1 2020 was Stonepine Capital Management, an estimated $608K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q1 2020 was Northern Trust, an estimated $43K sold.
Based on aggregated 13F filings for Q1 2020.